Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

States are ignoring federal guidelines, taking boosters into their own hands

The governors of Arkansas and West Virginia have announced that all fully vaccinated adults can receive a booster dose of a coronavirus vaccine, joining a growing list of states that are expanding access on their own rather than waiting on federal regulators to reconsider an earlier call reserving the shots for targeted vulnerable populations.

“People have got to get their booster shots – that’s all there is to it,” West Virginia Gov. Jim Justice said during a news conference Monday. “If you’re 18 and above, you can get that shot. And you need to get that booster shot because your level of protection right now is not much at all if you’re six months out.”

Source: US News

https://www.usnews.com/news/health-news/articles/2021-11-16/states-are-ignoring-federal-guidelines-taking-boosters-into-their-own-hands

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!